Home › Funds › Palo Alto Investors LP › SNDX
Palo Alto Investors LP position in SNDX
SYNDAX PHARMACEUTICALS INC · Health Care
Palo Alto Investors LP reported holding 596,356 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$11.2M, representing 1.67% of its reported portfolio and ranking #17 among its reported holdings. Palo Alto Investors LP has disclosed SNDX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's SNDX position evolved
Palo Alto Investors LP first disclosed a stake in SNDX in Q3 2023 at 472,600 shares (US$6.9M). The position peaked in Q1 2026 at 864,986 shares, worth US$20.2M. Across 13 filings, Palo Alto Investors LP increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 596,356 shares valued at US$11.2M — a reduction of -268,630 shares quarter over quarter.. Notable position changes include a 47% increase in Q3 2025 (shares rose 37% over the following quarter), a 31% trim in Q3 2026 (shares fell 51% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 472.60K | $6.86M | New |
| Q4 2023 | 472.60K | $10.21M | Hold |
| Q1 2024 | 405.19K | $9.64M | Reduce |
| Q2 2024 | 405.19K | $8.32M | Hold |
| Q3 2024 | 405.19K | $7.80M | Hold |
| Q4 2024 | 405.19K | $5.36M | Hold |
| Q1 2025 | 444.37K | $5.46M | Add |
| Q2 2025 | 444.37K | $4.16M | Hold |
| Q3 2025 | 654.93K | $10.08M | Add |
| Q4 2025 | 794.51K | $16.69M | Add |
| Q1 2026 | 864.99K | $20.21M | Add |
| Q2 2026 | 864.99K | $18.91M | Hold |
| Q3 2026 | 596.36K | $11.21M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SNDX and 13F data
SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$153.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$71.1M), Eversept Partners, LP (US$45.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SNDX
- Kynam Capital Management, LP 8.15M sh · $153.24M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.78M sh · $71.06M · Q3 2026
- Eversept Partners, LP 2.44M sh · $45.93M · Q3 2026
- Elmind Capital, LP 1.60M sh · $30.17M · Q3 2026
- Aisling Capital Management LP 1.32M sh · $24.76M · Q3 2026
- Parkman Healthcare Partners LLC 1.11M sh · $20.78M · Q3 2026
- Catalio Capital Management, LP 1.02M sh · $19.24M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held SNDX?
Palo Alto Investors LP has disclosed SNDX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Palo Alto Investors LP's current position in SNDX?
As of Q3 2026, Palo Alto Investors LP holds 596.36K shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $11.21M, representing 1.67% of its reported portfolio and ranking #17.
Has Palo Alto Investors LP been buying or selling SNDX?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in SNDX. The position peaked in Q1 2026 at 864.99K shares.
Which other funds hold SNDX?
Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.